| 引用本文: | 丁庆林,魏艳红,孙鸽,胡康洪.通过生物信息学分析鉴定CYB561与浸润性乳腺癌不良预后相关[J].生物信息学,2021,19(3):184-194. |
| DING Qinglin,WEI Yanhong,SUN Ge,HU Kanghong.Analysis of poor prognosis of breast invasive carcinoma associatedwith CYB561 through bioinformatics[J].Chinese Journal of Bioinformatics,2021,19(3):184-194. |
|
| |
|
|
| 本文已被：浏览 1169次 下载 19次 |
码上扫一扫！ |
|
|
| 通过生物信息学分析鉴定CYB561与浸润性乳腺癌不良预后相关 |
|
丁庆林,魏艳红,孙鸽,胡康洪
|
|
(湖北工业大学 生物工程与食品学院中德生物医学中心,湖北省工业微生物重点实验室,教育部及国家外专局“细胞调控与分子药物学科111创新引智基地”, 武汉 430068)
|
|
| 摘要: |
| 通过生物信息学研究细胞色素b561(Cytochromes b561, CYB561)与浸润性乳腺癌(Breast invasive carcinoma, BRCA)不良预后的相关性。CYB561氨基酸序列高度保守,在人体组织中广泛表达,可能预示着广泛的细胞功能。CYB561在多种癌症中的失调,提示其可能参与人类癌症发生发展进程。通过Oncomine和TIMER数据库发现,与相邻正常组织相比,CYB561表达在包括BRCA等多种癌症中差异表达。UALCAN数据库进行临床病理特征亚组分析表明,与正常人相比,不同种族和亚型的BRCA患者中CYB561的表达均上调。通过cBioPortal数据库发现CYB561基因组存在遗传变异,包括拷贝数扩增、融合和意义不明的错义突变。通过LinkedOmics和WebGestalt数据库分析CYB561和BRCA中差异表达的基因进行富集分析,可推测CYB561在BRCA中生物学功能。通过PrognoScan和GEPIA数据库分析CYB561的预后价值表明,高CYB561表达与BRCA不良预后显著相关。BRCA的预后存在着免疫细胞的参与,研究免疫细胞与CYB561表达之间的关系发现,免疫浸润的B细胞会影响预后,并且可能与BRCA中的CYB561有关。目前,对于CYB561研究较少,暂无CYB561关于BRCA的报道,我们通过不同的开放式数据库进行数据挖掘,研究了BRCA患者中CYB561表达和突变的数据,分析了其可能参与的生物学过程,并首次阐述了CYB561在BRCA中的失调且与不良预后相关。本研究为CYB561作为BRCA潜在的预后标志物提供了证据,揭示了CYB561的重要性,为进一步研究CYB561在BRCA中的作用奠定了基础,也为后续临床研究提供了参考。 |
| 关键词: 细胞色素b561(CYB561) 浸润性乳腺癌(BRCA) 免疫浸润 预后 |
| DOI：10.12113/202006009 |
| 分类号:R737.9 |
| 文献标识码:A |
| 基金项目:湖北工业大学高层次人才启动基金(No. 337203). |
|
| Analysis of poor prognosis of breast invasive carcinoma associatedwith CYB561 through bioinformatics |
|
DING Qinglin, WEI Yanhong, SUN Ge, HU Kanghong
|
|
(Hubei Provincial Key Laboratory of Industrial Microbiology, Sino-German Biomedical Center, National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan 430068, China)
|
| Abstract: |
| The purpose of this study is to investigate the correlation between cytochromes b561 (CYB561) and poor prognosis of breast invasive cancer (BRCA) through bioinformatics. The amino acid sequences of CYB561 are highly conserved and it is widely expressed in human tissues, which may imply a wide range of cell functions. The imbalance of CYB561 in a variety of cancers suggests that it may be involved in the development of human cancer. According to Oncomine and TIMER databases, CYB561 expression is differentially expressed in various cancers, including BRCA, compared with adjacent normal tissues. A subgroup analysis of clinicopathological characteristics using the UALCAN database showed that CYB561 expression was upregulated in BRCA patients of different races and subtypes compared with normal controls. Analysis of the cBioPortal database showed that there were genetic variations in the CYB561 genome, including copy number amplification, fusion, and missense mutations with unknown significance. By analyzing the differentially expressed genes in CYB561 and BRCA through the LinkedOmics and WebGestalt databases for enrichment analysis, the biological function of CYB561 in BRCA could be inferred. Analysis of the prognostic values of CYB561 by PrognoScan and GEPIA database showed that high CYB561 expression was significantly related to the poor prognosis of BRCA. Immune cells were involved in the prognosis of BRCA. The relationship between immune cells and the expression of CYB561 was studies. It was found that immune infiltrating B cells affected the prognosis, and it might be related to CYB561 in BRCA. Currently, there are few studies on CYB561, and there is no report of CYB561 on BRCA. We conducted data mining through different open databases, studied CYB561 expression and mutation data in BRCA patients, analyzed the biological processes that it may participate in, and found for the first time that CYB561 is dysregulated in BRCA and is associated with poor prognosis. This paper provides evidence for CYB561 as a potential prognostic biomarker for BRCA, reveals the importance of CYB561, lays a foundation for further study of the role of CYB561 in BRCA, and offers a valuable clue for subsequent clinical studies. |
| Key words: Cytochrome b561 (CYB561) Breast invasive cancer (BRCA) Immune infiltration Prognosis |
|
|
|
|
